Iliad Neurosciences

Iliad Neurosciences, Inc. is a Plymouth Meeting, PA based company established in 2013 with the goal of developing biomarkers and diagnostics for neurological diseases. Its first diagnostic product, FRAT™, screens for antibodies to the Folate Receptor A and is targeted towards children with Autism Spectrum Disorders and other neurological deficiencies. The company's research focuses on Folate Receptor Antibodies and Folate Metabolism in various neurodevelopment disorders. The management team, led by Boas Gonen, MD, Steven J. Adelman, and Steve Tsetsekos, brings decades of experience in R&D, drug discovery, therapeutic development, and finance. Iliad Neurosciences Inc. aims to make revolutionary discoveries in the diagnostic and therapeutic areas of Autism, Schizophrenia, Cerebral Folate Deficiency, Neural Tube Defects, Depression, Chronic Fatigue Syndrome, Multiple Sclerosis, and Parkinson’s.